1oi6
From Proteopedia
| Line 4: | Line 4: | ||
|PDB= 1oi6 |SIZE=350|CAPTION= <scene name='initialview01'>1oi6</scene>, resolution 1.40Å | |PDB= 1oi6 |SIZE=350|CAPTION= <scene name='initialview01'>1oi6</scene>, resolution 1.40Å | ||
|SITE= <scene name='pdbsite=AC1:Gol+Binding+Site+For+Chain+A'>AC1</scene> | |SITE= <scene name='pdbsite=AC1:Gol+Binding+Site+For+Chain+A'>AC1</scene> | ||
| - | |LIGAND= <scene name='pdbligand= | + | |LIGAND= <scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=TMP:THYMIDINE-5'-PHOSPHATE'>TMP</scene> |
|ACTIVITY= | |ACTIVITY= | ||
|GENE= | |GENE= | ||
| + | |DOMAIN= | ||
| + | |RELATEDENTRY= | ||
| + | |RESOURCES=<span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=1oi6 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=1oi6 OCA], [http://www.ebi.ac.uk/pdbsum/1oi6 PDBsum], [http://www.rcsb.org/pdb/explore.do?structureId=1oi6 RCSB]</span> | ||
}} | }} | ||
| Line 24: | Line 27: | ||
[[Category: Merkel, A B.]] | [[Category: Merkel, A B.]] | ||
[[Category: Naismith, J H.]] | [[Category: Naismith, J H.]] | ||
| - | [[Category: GOL]] | ||
| - | [[Category: TMP]] | ||
[[Category: epimerase]] | [[Category: epimerase]] | ||
[[Category: evad]] | [[Category: evad]] | ||
| Line 31: | Line 32: | ||
[[Category: vancomycin group antibiotic]] | [[Category: vancomycin group antibiotic]] | ||
| - | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sun Mar | + | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sun Mar 30 22:45:40 2008'' |
Revision as of 19:45, 30 March 2008
| |||||||
| , resolution 1.40Å | |||||||
|---|---|---|---|---|---|---|---|
| Sites: | |||||||
| Ligands: | , | ||||||
| Resources: | FirstGlance, OCA, PDBsum, RCSB | ||||||
| Coordinates: | save as pdb, mmCIF, xml | ||||||
STRUCTURE DETERMINATION OF THE TMP-COMPLEX OF EVAD
Overview
Vancomycin, the last line of defense antibiotic, depends upon the attachment of the carbohydrate vancosamine to an aglycone skeleton for antibacterial activity. Vancomycin is a naturally occurring secondary metabolite that can be produced by bacterial fermentation. To combat emerging resistance, it has been proposed to genetically engineer bacteria to produce analogues of vancomycin. This requires a detailed understanding of the biochemical steps in the synthesis of vancomycin. Here we report the 1.4 A structure and biochemical characterization of EvaD, an RmlC-like protein that is required for the C-5' epimerization during synthesis of dTDP-epivancosamine. EvaD, although clearly belonging to the RmlC class of enzymes, displays very low activity in the archetypal RmlC reaction (double epimerization of dTDP-6-deoxy-4-keto-D-glucose at C-3' and C-5'). The high resolution structure of EvaD compared with the structures of authentic RmlC enzymes indicates that a subtle change in the enzyme active site repositions a key catalytic Tyr residue. A mutant designed to re-establish the normal position of the Tyr increases the RmlC-like activity of EvaD.
About this Structure
1OI6 is a Single protein structure of sequence from Amycolatopsis orientalis. Full crystallographic information is available from OCA.
Reference
The position of a key tyrosine in dTDP-4-Keto-6-deoxy-D-glucose-5-epimerase (EvaD) alters the substrate profile for this RmlC-like enzyme., Merkel AB, Major LL, Errey JC, Burkart MD, Field RA, Walsh CT, Naismith JH, J Biol Chem. 2004 Jul 30;279(31):32684-91. Epub 2004 May 24. PMID:15159413
Page seeded by OCA on Sun Mar 30 22:45:40 2008
